Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNYSE:INFUNASDAQ:NPCENASDAQ:SMLR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$10.04-1.3%$13.52$6.59▼$21.00$457.26M1.05476,716 shs550,291 shsINFUInfuSystem$6.10+0.2%$5.36$4.61▼$9.97$128.20M1.8198,579 shs86,359 shsNPCENeuroPace$11.23-5.1%$12.87$5.45▼$18.98$368.33M2.03167,310 shs331,191 shsSMLRSemler Scientific$30.74-3.1%$35.61$21.77▼$81.56$342.81M1.42510,074 shs813,807 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-4.78%-6.70%-10.71%-40.73%+37.80%INFUInfuSystem+0.66%-0.16%+11.13%+11.54%-14.71%NPCENeuroPace-8.58%-10.17%-11.52%+13.42%+85.42%SMLRSemler Scientific+0.70%-11.30%-8.96%-2.76%-20.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.3524 of 5 stars3.52.00.00.01.62.50.6INFUInfuSystem2.2384 of 5 stars2.03.00.00.00.64.21.9NPCENeuroPace3.7413 of 5 stars3.45.00.00.02.54.20.6SMLRSemler Scientific2.9033 of 5 stars3.52.00.00.02.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20121.12% UpsideINFUInfuSystem 4.00Strong Buy$13.00113.11% UpsideNPCENeuroPace 2.83Moderate Buy$15.5038.02% UpsideSMLRSemler Scientific 3.00Buy$71.00130.97% UpsideCurrent Analyst Ratings BreakdownLatest INFU, AXGN, NPCE, and SMLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/18/2025INFUInfuSystemSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025AXGNAxoGenLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$194.52M2.35N/AN/A$2.22 per share4.52INFUInfuSystem$137.58M0.93$0.48 per share12.79$2.47 per share2.47NPCENeuroPace$84.31M4.37N/AN/A$0.79 per share14.22SMLRSemler Scientific$49.23M6.96$1.81 per share16.95$10.45 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.15N/AN/AN/A-7.91%-14.91%-7.49%8/14/2025 (Estimated)INFUInfuSystem$870K$0.14101.6819.68N/A1.12%2.78%1.41%N/ANPCENeuroPace-$32.96M-$0.84N/AN/AN/A-36.74%-205.41%-28.29%8/12/2025 (Estimated)SMLRSemler Scientific$20.58M-$2.616.26∞N/A72.65%50.77%47.04%8/4/2025 (Estimated)Latest INFU, AXGN, NPCE, and SMLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/13/2025Q1 2025SMLRSemler ScientificN/A-$0.76N/A-$6.74N/A$8.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ASMLRSemler ScientificN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47INFUInfuSystem0.501.981.59NPCENeuroPace6.035.594.77SMLRSemler ScientificN/A3.143.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%INFUInfuSystem71.13%NPCENeuroPace78.83%SMLRSemler Scientific49.37%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%INFUInfuSystem11.40%NPCENeuroPace22.20%SMLRSemler Scientific30.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million40.93 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableNPCENeuroPace17032.80 million23.22 millionOptionableSMLRSemler Scientific12011.15 million6.47 millionNot OptionableINFU, AXGN, NPCE, and SMLR HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Semler Scientific, Inc. (SMLR) And Encourages Shareholders to Reach OutJune 12 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 12 at 9:00 AM | prnewswire.comROSEN, A TOP-RANKED FIRM, Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 11 at 9:37 PM | accessnewswire.comTom Lee Mulls Roughed-Up Semler Scientific for 'Granny Shot' PortfolioJune 11 at 4:11 PM | coindesk.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Semler Scientific, Inc. (SMLR) and Encourages Shareholders to Learn More About the InvestigationJune 11 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 11 at 9:00 AM | accessnewswire.comRosen Law Firm Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 10 at 6:14 PM | prnewswire.comTraders Purchase Large Volume of Semler Scientific Call Options (NASDAQ:SMLR)June 10 at 11:12 AM | marketbeat.comSemler Scientific, Inc. (SMLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the InvestigationJune 10 at 10:00 AM | accessnewswire.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. ...June 9 at 3:07 PM | gurufocus.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 9 at 3:00 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 9 at 12:45 PM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Semler Scientific, Inc. (SMLR) Shareholders to Inquire about Securities InvestigationJune 9 at 10:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Semler Scientific, Inc. (SMLR) And Encourages Investors to ConnectJune 8, 2025 | accessnewswire.comSMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You ...June 7, 2025 | bakersfield.comSemler Scientific Inc call volume above normal and directionally bullishJune 7, 2025 | msn.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLRJune 7, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Semler Scientific Inc. - SMLRJune 6, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Semler Scientific, Inc. (SMLR) Stockholders to Inquire about Securities InvestigationJune 6, 2025 | accessnewswire.comSemler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLPJune 5, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsToyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock INFU, AXGN, NPCE, and SMLR Company DescriptionsAxoGen NASDAQ:AXGN$10.04 -0.13 (-1.28%) As of 04:00 PM EasternAxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.InfuSystem NYSE:INFU$6.10 +0.01 (+0.16%) As of 04:00 PM EasternInfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.NeuroPace NASDAQ:NPCE$11.23 -0.60 (-5.07%) As of 04:00 PM EasternNeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Semler Scientific NASDAQ:SMLR$30.74 -0.98 (-3.09%) As of 04:00 PM EasternSemler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
